Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism

Alexandra Collin de l'Hortet, Kazuki Takeishi, J. Guzman-Lepe, Kazutoyo Morita, Abhinav Achreja, Branimir Popovic, Yang Wang, Kan Handa, Anjali Mittal, Noah Meurs, Z. Zhu, F. Weinberg, Michael Salomon, I. J. Fox, Chu Xia Deng, Deepak Nagrath, Alejandro Soto-Gutierrez

Research output: Contribution to journalArticle

Abstract

The mechanisms by which steatosis of the liver progresses to non-alcoholic steatohepatitis and end-stage liver disease remain elusive. Metabolic derangements in hepatocytes controlled by SIRT1 play a role in the development of fatty liver in inbred animals. The ability to perform similar studies using human tissue has been limited by the genetic variability in man. We generated human induced pluripotent stem cells (iPSCs) with controllable expression of SIRT1. By differentiating edited iPSCs into hepatocytes and knocking down SIRT1, we found increased fatty acid biosynthesis that exacerbates fat accumulation. To model human fatty livers, we repopulated decellularized rat livers with human mesenchymal cells, fibroblasts, macrophages, and human SIRT1 knockdown iPSC-derived hepatocytes and found that the human iPSC-derived liver tissue developed macrosteatosis, acquired proinflammatory phenotype, and shared a similar lipid and metabolic profiling to human fatty livers. Biofabrication of genetically edited human liver tissue may become an important tool for investigating human liver biology and disease. Collin de l'Hortet et al. biofabricated human fatty livers using genetically modified human hepatocytes differentiated from induced pluripotent stem cells, mesenchymal cells, fibroblasts, and macrophages. This methodology uncovered the molecular mechanisms of downregulated SIRT1 in human liver tissue. The biofabricated tissue reflected many aspects of human livers with non-alcoholic fatty liver disease.

Original languageEnglish
Pages (from-to)385-401.e9
JournalCell metabolism
Volume30
Issue number2
DOIs
Publication statusPublished - Aug 6 2019

Fingerprint

Induced Pluripotent Stem Cells
Fatty Liver
Hepatocytes
Liver
Fibroblasts
Macrophages
End Stage Liver Disease
Liver Diseases
Fatty Acids
Down-Regulation
Fats

All Science Journal Classification (ASJC) codes

  • Physiology
  • Molecular Biology
  • Cell Biology

Cite this

Collin de l'Hortet, A., Takeishi, K., Guzman-Lepe, J., Morita, K., Achreja, A., Popovic, B., ... Soto-Gutierrez, A. (2019). Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism. Cell metabolism, 30(2), 385-401.e9. https://doi.org/10.1016/j.cmet.2019.06.017

Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism. / Collin de l'Hortet, Alexandra; Takeishi, Kazuki; Guzman-Lepe, J.; Morita, Kazutoyo; Achreja, Abhinav; Popovic, Branimir; Wang, Yang; Handa, Kan; Mittal, Anjali; Meurs, Noah; Zhu, Z.; Weinberg, F.; Salomon, Michael; Fox, I. J.; Deng, Chu Xia; Nagrath, Deepak; Soto-Gutierrez, Alejandro.

In: Cell metabolism, Vol. 30, No. 2, 06.08.2019, p. 385-401.e9.

Research output: Contribution to journalArticle

Collin de l'Hortet, A, Takeishi, K, Guzman-Lepe, J, Morita, K, Achreja, A, Popovic, B, Wang, Y, Handa, K, Mittal, A, Meurs, N, Zhu, Z, Weinberg, F, Salomon, M, Fox, IJ, Deng, CX, Nagrath, D & Soto-Gutierrez, A 2019, 'Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism', Cell metabolism, vol. 30, no. 2, pp. 385-401.e9. https://doi.org/10.1016/j.cmet.2019.06.017
Collin de l'Hortet, Alexandra ; Takeishi, Kazuki ; Guzman-Lepe, J. ; Morita, Kazutoyo ; Achreja, Abhinav ; Popovic, Branimir ; Wang, Yang ; Handa, Kan ; Mittal, Anjali ; Meurs, Noah ; Zhu, Z. ; Weinberg, F. ; Salomon, Michael ; Fox, I. J. ; Deng, Chu Xia ; Nagrath, Deepak ; Soto-Gutierrez, Alejandro. / Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism. In: Cell metabolism. 2019 ; Vol. 30, No. 2. pp. 385-401.e9.
@article{5ccc5b2f8ea34de593323e8f0a04eff8,
title = "Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism",
abstract = "The mechanisms by which steatosis of the liver progresses to non-alcoholic steatohepatitis and end-stage liver disease remain elusive. Metabolic derangements in hepatocytes controlled by SIRT1 play a role in the development of fatty liver in inbred animals. The ability to perform similar studies using human tissue has been limited by the genetic variability in man. We generated human induced pluripotent stem cells (iPSCs) with controllable expression of SIRT1. By differentiating edited iPSCs into hepatocytes and knocking down SIRT1, we found increased fatty acid biosynthesis that exacerbates fat accumulation. To model human fatty livers, we repopulated decellularized rat livers with human mesenchymal cells, fibroblasts, macrophages, and human SIRT1 knockdown iPSC-derived hepatocytes and found that the human iPSC-derived liver tissue developed macrosteatosis, acquired proinflammatory phenotype, and shared a similar lipid and metabolic profiling to human fatty livers. Biofabrication of genetically edited human liver tissue may become an important tool for investigating human liver biology and disease. Collin de l'Hortet et al. biofabricated human fatty livers using genetically modified human hepatocytes differentiated from induced pluripotent stem cells, mesenchymal cells, fibroblasts, and macrophages. This methodology uncovered the molecular mechanisms of downregulated SIRT1 in human liver tissue. The biofabricated tissue reflected many aspects of human livers with non-alcoholic fatty liver disease.",
author = "{Collin de l'Hortet}, Alexandra and Kazuki Takeishi and J. Guzman-Lepe and Kazutoyo Morita and Abhinav Achreja and Branimir Popovic and Yang Wang and Kan Handa and Anjali Mittal and Noah Meurs and Z. Zhu and F. Weinberg and Michael Salomon and Fox, {I. J.} and Deng, {Chu Xia} and Deepak Nagrath and Alejandro Soto-Gutierrez",
year = "2019",
month = "8",
day = "6",
doi = "10.1016/j.cmet.2019.06.017",
language = "English",
volume = "30",
pages = "385--401.e9",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism

AU - Collin de l'Hortet, Alexandra

AU - Takeishi, Kazuki

AU - Guzman-Lepe, J.

AU - Morita, Kazutoyo

AU - Achreja, Abhinav

AU - Popovic, Branimir

AU - Wang, Yang

AU - Handa, Kan

AU - Mittal, Anjali

AU - Meurs, Noah

AU - Zhu, Z.

AU - Weinberg, F.

AU - Salomon, Michael

AU - Fox, I. J.

AU - Deng, Chu Xia

AU - Nagrath, Deepak

AU - Soto-Gutierrez, Alejandro

PY - 2019/8/6

Y1 - 2019/8/6

N2 - The mechanisms by which steatosis of the liver progresses to non-alcoholic steatohepatitis and end-stage liver disease remain elusive. Metabolic derangements in hepatocytes controlled by SIRT1 play a role in the development of fatty liver in inbred animals. The ability to perform similar studies using human tissue has been limited by the genetic variability in man. We generated human induced pluripotent stem cells (iPSCs) with controllable expression of SIRT1. By differentiating edited iPSCs into hepatocytes and knocking down SIRT1, we found increased fatty acid biosynthesis that exacerbates fat accumulation. To model human fatty livers, we repopulated decellularized rat livers with human mesenchymal cells, fibroblasts, macrophages, and human SIRT1 knockdown iPSC-derived hepatocytes and found that the human iPSC-derived liver tissue developed macrosteatosis, acquired proinflammatory phenotype, and shared a similar lipid and metabolic profiling to human fatty livers. Biofabrication of genetically edited human liver tissue may become an important tool for investigating human liver biology and disease. Collin de l'Hortet et al. biofabricated human fatty livers using genetically modified human hepatocytes differentiated from induced pluripotent stem cells, mesenchymal cells, fibroblasts, and macrophages. This methodology uncovered the molecular mechanisms of downregulated SIRT1 in human liver tissue. The biofabricated tissue reflected many aspects of human livers with non-alcoholic fatty liver disease.

AB - The mechanisms by which steatosis of the liver progresses to non-alcoholic steatohepatitis and end-stage liver disease remain elusive. Metabolic derangements in hepatocytes controlled by SIRT1 play a role in the development of fatty liver in inbred animals. The ability to perform similar studies using human tissue has been limited by the genetic variability in man. We generated human induced pluripotent stem cells (iPSCs) with controllable expression of SIRT1. By differentiating edited iPSCs into hepatocytes and knocking down SIRT1, we found increased fatty acid biosynthesis that exacerbates fat accumulation. To model human fatty livers, we repopulated decellularized rat livers with human mesenchymal cells, fibroblasts, macrophages, and human SIRT1 knockdown iPSC-derived hepatocytes and found that the human iPSC-derived liver tissue developed macrosteatosis, acquired proinflammatory phenotype, and shared a similar lipid and metabolic profiling to human fatty livers. Biofabrication of genetically edited human liver tissue may become an important tool for investigating human liver biology and disease. Collin de l'Hortet et al. biofabricated human fatty livers using genetically modified human hepatocytes differentiated from induced pluripotent stem cells, mesenchymal cells, fibroblasts, and macrophages. This methodology uncovered the molecular mechanisms of downregulated SIRT1 in human liver tissue. The biofabricated tissue reflected many aspects of human livers with non-alcoholic fatty liver disease.

UR - http://www.scopus.com/inward/record.url?scp=85068939484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068939484&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2019.06.017

DO - 10.1016/j.cmet.2019.06.017

M3 - Article

AN - SCOPUS:85068939484

VL - 30

SP - 385-401.e9

JO - Cell Metabolism

JF - Cell Metabolism

SN - 1550-4131

IS - 2

ER -